Latest news with #GlucagonforInjectionUSP
The Hindu
4 days ago
- Health
- The Hindu
Lupin launches generic diabetes drug in U.S.
Generic drugmaker Lupin has launched Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the U.S. Bioequivalent of Eli Lilly and Company's Glucagon for Injection, 1 mg/vial, the product is indicated for treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. It is also used as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. Glucagon for Injection USP, 1mg/vial packaged in an emergency kit, had an estimated annual sale of $122 million in the U.S., Lupin said in a release on Monday citing IQVIA MAT June 2025 numbers. It had received U.S. FDA approval for this and another generic diabetes drug in July. Lupin shares closed 1.53% at ₹1,946.15 each on the BSE.
Business Standard
5 days ago
- Health
- Business Standard
Lupin launches Glucagon for Injection USP, 1mg/vial in US market
Lupin today announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the United States. Glucagon for Injection USP, 1mg/vial packaged in an emergency kit is bioequivalent to Glucagon for Injection, 1 mg/vial of Eli Lilly and Company. Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the U.S. (IQVIA MAT June 2025).
Business Standard
5 days ago
- Business
- Business Standard
Lupin gains after launching Glucagon for Injection in U.S. market
Lupin rose 1.04% to Rs 1,936.75 after the company announced the launch of Glucagon for Injection USP, 1 mg/vial, packaged in an emergency kit, in the United States. The product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, and is used in the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes mellitus. It is also indicated as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal motility in adult patients. According to IQVIA MAT (June 2025) data, Glucagon for Injection USP, 1 mg/vial packaged in an emergency kit, had estimated annual sales of $122 million in the U.S. market. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupins consolidated net profit jumped 52.13% to Rs 1,219.03 crore on 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25.
News18
5 days ago
- Health
- News18
Lupin launches generic medication in US
Agency: PTI Last Updated: New Delhi, Aug 11 (PTI) Drug maker Lupin on Monday said it has launched a medication, used to regulate blood glucose levels, in the US market. The company has launched Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the US, the Mumbai-based drug maker said in a statement. The company's product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, it added. Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. As per IQVIA MAT June data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the US. PTI MSS DRR DRR First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Upturn
5 days ago
- Health
- Business Upturn
Lupin launches Glucagon for Injection in the U.S. market
By Aditya Bhagchandani Published on August 11, 2025, 10:30 IST Global pharmaceutical major Lupin Limited has announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit, in the United States. The product is bioequivalent to Eli Lilly's Glucagon for Injection, 1mg/vial. Glucagon is indicated for treating severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adults. According to IQVIA MAT June 2025 data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit recorded estimated annual U.S. sales of USD 122 million. Lupin, headquartered in Mumbai, operates in over 100 markets with a strong presence in India and the U.S. across multiple therapy areas. The company runs 15 manufacturing sites and seven research centers globally, supported by over 23,000 employees. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
